Literature DB >> 29862545

Evolving treatment strategies in CML - moving from early and deep molecular responses to TKI discontinuation and treatment-free remission: is there a need for longer-term trial outcomes?

Ahmet Emre Eşkazan1.   

Abstract

Keywords:  chronic myeloid leukaemia; deep molecular response; discontinuation; early molecular response; treatment-free remission; tyrosine kinase inhibitor

Mesh：

Substances：

Year:  2018        PMID： 29862545      PMCID： PMC6046500          DOI： 10.1111/bcp.13637

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  29 in total

1.  Tyrosine kinase inhibitor (TKI) therapy for newly-diagnosed patients with chronic myeloid leukemia: focusing on TKI discontinuation due to adverse events - is better always good?

Authors:  Ahmet Emre Eskazan; Deniz Ozmen
Journal:  Expert Rev Hematol       Date:  2017-06-13       Impact factor: 2.929

Review 2.  Considerations for Successful Treatment-free Remission in Chronic Myeloid Leukemia.

Authors:  Stuart L Goldberg; Michael Savona; Michael J Mauro
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2017-11-29

Review 3.  How I manage relapse of chronic myeloid leukaemia after stopping tyrosine kinase inhibitor therapy.

Authors:  Delphine Rea; François-Xavier Mahon
Journal:  Br J Haematol       Date:  2017-10-19       Impact factor: 6.998

4.  The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.

Authors: 
Journal:  Blood       Date:  2013-04-25       Impact factor: 22.113

5.  Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

Authors:  Stephen G O'Brien; François Guilhot; Richard A Larson; Insa Gathmann; Michele Baccarani; Francisco Cervantes; Jan J Cornelissen; Thomas Fischer; Andreas Hochhaus; Timothy Hughes; Klaus Lechner; Johan L Nielsen; Philippe Rousselot; Josy Reiffers; Giuseppe Saglio; John Shepherd; Bengt Simonsson; Alois Gratwohl; John M Goldman; Hagop Kantarjian; Kerry Taylor; Gregor Verhoef; Ann E Bolton; Renaud Capdeville; Brian J Druker
Journal:  N Engl J Med       Date:  2003-03-13       Impact factor: 91.245

6.  Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.

Authors:  Jorge E Cortes; Dong-Wook Kim; Hagop M Kantarjian; Tim H Brümmendorf; Irina Dyagil; Laimonas Griskevicius; Hemant Malhotra; Christine Powell; Karïn Gogat; Athena M Countouriotis; Carlo Gambacorti-Passerini
Journal:  J Clin Oncol       Date:  2012-09-04       Impact factor: 44.544

7.  Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial.

Authors:  Jorge E Cortes; Giuseppe Saglio; Hagop M Kantarjian; Michele Baccarani; Jiří Mayer; Concepción Boqué; Neil P Shah; Charles Chuah; Luis Casanova; Brigid Bradley-Garelik; George Manos; Andreas Hochhaus
Journal:  J Clin Oncol       Date:  2016-05-23       Impact factor: 44.544

8.  Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.

Authors:  Giuseppe Saglio; Dong-Wook Kim; Surapol Issaragrisil; Philipp le Coutre; Gabriel Etienne; Clarisse Lobo; Ricardo Pasquini; Richard E Clark; Andreas Hochhaus; Timothy P Hughes; Neil Gallagher; Albert Hoenekopp; Mei Dong; Ariful Haque; Richard A Larson; Hagop M Kantarjian
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

9.  The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY.

Authors:  Simon D Harding; Joanna L Sharman; Elena Faccenda; Chris Southan; Adam J Pawson; Sam Ireland; Alasdair J G Gray; Liam Bruce; Stephen P H Alexander; Stephen Anderton; Clare Bryant; Anthony P Davenport; Christian Doerig; Doriano Fabbro; Francesca Levi-Schaffer; Michael Spedding; Jamie A Davies
Journal:  Nucleic Acids Res       Date:  2018-01-04       Impact factor: 16.971

Review 10.  Deep molecular responses for treatment-free remission in chronic myeloid leukemia.

Authors:  Stéphanie Dulucq; Francois-Xavier Mahon
Journal:  Cancer Med       Date:  2016-07-01       Impact factor: 4.452
View more
  2 in total

1.  Tyrosine kinase inhibitors (TKIs) used in the management of chronic myeloid leukaemia are associated with haematologic toxicities-Which TKI is the safest?

Authors:  Ahmet Emre Eşkazan
Journal:  Br J Clin Pharmacol       Date:  2019-08-22       Impact factor: 4.335

2.  Chronic myeloid leukaemia and the use of tyrosine kinase inhibitors in the days of COVID-19 pandemic.

Authors:  Ahmet Emre Eşkazan
Journal:  Br J Clin Pharmacol       Date:  2020-05-20       Impact factor: 4.335
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.